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and Signs Pain Scale (S-LANSS); and, 3. factors associated with
NP symptoms as measured by the mPD-Q.
Methods: Eligible participants were members of an established
population-based OA cohort with chronic symptomatic knee OA.
A standardized questionnaire was mailed to 426 cohort members
to assess NP symptoms (mPD-Q, S-LANSS); osteoarthritis status
(WOMAC, Von Korff Chronic Pain Grade); psychological factors
including depression (Center for Epidemiological Studies Depres-
sion Scale), anxiety (Hospital Anxiety and Depression scale) pain
catastrophizing (Pain Catastrophizing Scale), and sleepiness (Ep-
worth Daytime Sleepiness scale); co-morbid medical conditions;
possible confounding neurological conditions; and medication use.
The cut-point score (≥19) identiﬁed in other chronic pain popu-
lations was used to identify NP symptoms (‘NP range’ scores) in
this study. The proportion of knee OA participants with mPD-Q
scores in the NP range was calculated using a 95% conﬁdence
interval (CI). Spearman’s correlation between continuous mPD-Q
and S-LANSS scores was examined. Potential correlates of NP
symptoms were ﬁrst assessed using bivariate analysis, followed
by logistic regression modeling.
Results: Out of 426 cohort members who were sent a study
questionnaire, 259 were deemed eligible to participate. The re-
sponse rate among eligible cohort members was 66% (171/259).
The proportion (95% CI) of participants with mPD-Q scores in
the NP range was 0.28 (0.21-0.35). After removal of participants
with neurological conditions, 0.19 (0.12-0.29) still had scores in
the NP range. Continuous mPD-Q scores were highly correlated
with continuous S-LANSS scores. NP range scores were strongly
associated with OA severity, depressive and anxious symptoms,
pain catastrophizing, and a higher frequency of neurological con-
ditions, and chronic back or hip pain with radiation down either
leg (‘pain radiation’). On multivariable analysis, pain intensity, ‘pain
radiation’, and neurological conditions were independently related
to NP range scores.
Conclusions: A substantial proportion of older adults with chronic
symptomatic knee OA had symptoms of NP on the mPD-Q sug-
gesting neuropathic mechanisms may be contributing to their pain
experience. This subgroup of people may beneﬁt from further
evaluation for NP and consideration of NP medications. Validation
work is ongoing on the mPD-Q, which may serve as a clinically
feasible tool to aid the identiﬁcation of NP in people with OA.
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Purpose: Selective activation of peripheral receptors has the im-
portant advantage of providing effective analgesia without side
effects typically associated with centrally acting drugs. Several
data suggest that both opioid and NMDA receptors are local-
ized at peripheral level, and drugs acting on these receptors may
produce antinociception after topical administration, however, the
antinociceptive effect of endogenous ligands at these receptors is
poorly clariﬁed. It is also well known that the organism can express
very effective antinociception in different circumstances by releas-
ing of various endogenous ligands. The goal of this study was to
determine the antinociceptive potency of the endogenous opioid
peptide, endomorphin-1, and the endogenous NMDA receptor an-
tagonist, kynurenic acid and their interaction at peripheral level in
the rat inﬂamed joint model.
Methods: Mechanical hypersensitivity was produced by injection
of carrageenan (300μg/20μl) into the tibiotarsal joint of the right
hind leg. The mechanical pain threshold, the withdrawal from me-
chanical stimulation to the plantar aspect of the hindpaws, was
assessed by logarithmic series of calibrated von Frey monoﬁl-
aments (0.064-110 g). Endomorphin-1 (30, 100 and 200 μg),
kynurenic acid (30, 100, 200 and 400 μg) and their combinations
in a ﬁxed-dose ratio: (1:1) were given into the inﬂamed joint 3
hours after the induction of inﬂammation, and the pain threshold
was determined repeatedly for 75 min after the drug administra-
tions. To determine the changes in the size of the inﬂamed joint,
the cross section area of ankle joint was also calculated.
Results: None of the treatments inﬂuenced the degree of edema.
Neither endomorphin-1 nor kynurenic acid administered to the
inﬂamed joint inﬂuenced the pain threshold at the non-inﬂamed
side. Both ligands produced dose-dependent anti-hyperalgesia,
and the highest doses caused prolonged effect. Endomorphin-
1 had higher potency (ED50 value was 112 μg [CI: 80-146])
compared to kynurenic acid (ED50 value was 204 μg [CI: 160-
251]). The coadministration of endomorphin-1 with kynurenic acid
caused potentiated and/or prolonged antinociceptive effect. The
ED50 value of the combination was 141 μg [CI: 83-182], which did
not differ signiﬁcantly from the theoretically additive value (ED50
145 μg [CI: 68-237]), thus the interaction between these ligands is
additive. None of the treatments caused any sign of side-effects.
Conclusions: This study has shown that the intra-articularly ad-
ministered endogenous μ-opioid receptor agonist EM1 and the
NMDA receptor antagonist KYNA dose-dependently decreased
the mechanical allodynia without signs of systemic side effects.
The coadministration of these ligands produced additive interac-
tion, thus a decreased dose of each drug can lead to effective
antinociception. Furthermore, we did not ﬁnd any changes on the
normal side. Therefore, we may exclude systemic antinocicep-
tive effects of these ligands. These results suggest an important
direction for the development of pain strategies that focus on
the coadministration of different endogenous ligands at peripheral
level.
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Purpose: To evaluate the construct validation of behavioural and
physiologic tools to measure orthopaedic pain induced in an ex-
perimental canine osteoarthritis (OA) model. We hypothesized
that these methods will present different validity and reliability be-
tween placebo-controlled and anti-resorptive (tiludronate)-treated
dogs. This drug was chosen for its potential as pain-killer without
sedative activity.
Methods: This prospective randomized blinded study was per-
formed on healthy adult dogs divided into two groups: Group 1,
eight control dogs, and Group 2, eight tiludronate-treated dogs,
2 mg/kg, subcutaneous. Under standardized procedures, transec-
tion of the right anterior cruciate ligament was carried out at Day
(D) 0. Treatments were repeated every two weeks from D0 to D56.
Two observers, blinded to treatment, assessed pain using the
visual analog scale (VAS) and multiparametric pain scale (Stan-
dardized Technician Arthritis Pain Scale [STAPS]/Observer 1 and
Standardized Veterinarian Arthritis Pain Scale [SVAPS]/Observer
2). Objective methods comprised podobarometric gait analysis
to record peak vertical force (PVF), locomotor activity record-
